Figure 2.

Imaging changes of targeted therapy. The patient developed extensively after radiotherapy and chemotherapy and performed a PET-CT examination (A) on 16 November 2016. Vemurafenib was indicated as a potential benefit drug after NGS. CT scans 2 (B) and 4 (C) months later confirmed its effectiveness. However, CT examination on 19 Jun 2017 (D) found extensive progress in the lung and a second NGS was carried out. Everolimus might be another beneficial drug and the patient took everolimus along with vemurafenib. CT examination on 27 July 2017 (E) suggested lung lesions shrank again.